Gastroenterology
Conference Coverage
Biosimilars Have Driven Down Cost of Infliximab
Two studies show significant cost declines, but it remains unclear if patients see savings or access to the agents has improved.
From the Journals
NEJM Study Highlights Resmetirom’s Efficacy in NASH With Liver Fibrosis
Although to date the MAESTRO-NASH trial lacks clinical outcomes, over its planned duration of 54 months, investigators will accrue data on liver-...
Conference Coverage
In Refractory IBD, Combination Therapies Appear Safe, Effective
Updated meta-analysis names combination with highest response and remission rates and fewest adverse events.
News
Telephone Best for Switching Patients to New Colonoscopy Intervals
Telephone outreach may be a reasonable approach to update patients on post-polypectomy surveillance guideline changes if secure messaging or text...
From the Journals
New Guideline Offers Recommendations for Alcohol-Associated Liver Disease
The guidelines note the importance of policy aimed at alcohol use reduction, multidisciplinary care for alcohol use disorder and alcohol-...
Latest News
Migraine Associated With Increased Risk for IBD
Population-based study finds link between migraine and increased risk of IBD, Crohn’s, and UC.
Conference Coverage
Cell-Free DNA May Inform IBD Diagnosis
Noninvasive test’s sensitivity and specificity compare favorably with standard of care measures.
From the Journals
More Side Effects With Local Therapies for Prostate Cancer
What impact does local therapy have on the men’s quality of life?
Latest News
FDA Expands Dupilumab for EoE to Younger Children
EoE drug approval expanded to include children age 1 to 11, following approval in children 12 and older.
Conference Coverage
Wearable Device Tracks IBD from Sweat
If perfected, noninvasive method could improve patient management and provide more granular data for clinical studies.
Latest News
Etrasimod Appears Effective in Eosinophilic Esophagitis: Phase 2 Study
Among patients given a 1-mg daily dose of etrasimod, there was a 27.4% reduction in peak eosinophil count.